An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive...

Area of Science:

• Psychiatry
• Clinical Psychology
• Pharmacology

Background:

• Major depressive disorder (MDD) frequently co-occurs with borderline personality disorder (BPD).
• Comorbidity of BPD and MDD may impact treatment outcomes for depression.
• Psilocybin is being investigated for its therapeutic potential in various mental health conditions.

Purpose of the Study:

• To investigate the efficacy of psilocybin in treating adults with comorbid MDD and BPD.
• To assess the impact of psilocybin on both depressive and BPD symptoms.

Main Methods:

• An open-label pilot study involving adults (18-65 years) diagnosed with MDD and BPD.
• Participants received a single dose of psilocybin.
• Symptom assessments for MDD and BPD were conducted at baseline and at 1, 2, and 4 weeks post-dosing.

Main Results:

• Nine participants with MDD and BPD were enrolled.
• A statistically significant reduction in MDD symptoms was observed from baseline to the final visit (P=0.003).
• No significant changes were found in BPD symptom scores from baseline to endpoint.

Conclusions:

• Psilocybin treatment led to significant improvement in depressive symptoms for individuals with comorbid MDD and BPD.
• Borderline personality disorder symptoms did not significantly improve in this pilot study.
• These preliminary findings suggest that BPD comorbidity may not impede the antidepressant response to psilocybin, warranting further investigation in larger trials.